Pharmacological chaperones for treating obesity
View Patent ↗The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.
1. A method for treating obesity in an individual having a mutant MC4R polypeptide associated with misfolding of the MC4R polypeptide, the method comprising:
administering to the individual a pharmacological chaperone that binds to the mutant MC4R polypeptide, wherein the pharmacological chaperone has the structure of formula 23:
wherein the pharmacological chaperone is administered in an amount effective to increase the mutant MC4R polypeptide activity.
2. The method of claim 1 , wherein the pharmacological chaperone is administered in a pharmaceutically-acceptable carrier.
3. The method of claim 1 , wherein the pharmacological chaperone is administered orally.
4. The method of claim 1 , wherein increasing the mutant MC4R polypeptide activity comprises increasing cAMP activation.
5. The method of claim 1 , wherein the mutant MC4R polypeptide comprises the mutation P78L, R165Q, R165W, C271Y, T11A, A175T, I316L, I1316S, I317T, N97D, G98R, N62S, C271R, S58C, N97D, Y157S, I102S, L106P, L250Q or Y287X.
6. The method of claim 5 , wherein the mutant MC4R polypeptide comprises the mutation S58C, N62S, R165Q, R165W, or C271Y.
7. A method for treating obesity in an individual having a mutant MC4R polypeptide associated with misfolding of the MC4R polypeptide, the method comprising:
administering to the individual a pharmacological chaperone that binds to the mutant MC4R polypeptide, wherein the pharmacological chaperone has the structure of formula 23:
wherein the pharmacological chaperone is administered in an amount effective to increase mutant MC4R cell surface expression.
8. The method of claim 7 , wherein the pharmacological chaperone is administered in a pharmaceutically-acceptable carrier.
9. The method of claim 7 , wherein the pharmacological chaperone is administered orally.
10. The method of claim 7 , wherein the mutant MC4R polypeptide comprises the mutation P78L, R165Q, R165W, C271Y, T11A, A175T, I316L, 1316S, I317T, N97D, G98R, N62S, C271R, S58C, N97D, Y157S, I102S, L106P, L250Q or Y287X.
11. The method of claim 10 , wherein the mutant MC4R polypeptide comprises the mutation S58C, N62S, R165Q, R165W, or C271Y.
12. A method for treating obesity in an individual having a mutant MC4R polypeptide associated with misfolding of the MC4R polypeptide, the method comprising:
administering to the individual a pharmacological chaperone that binds to the mutant MC4R polypeptide, wherein the pharmacological chaperone has the structure of formula 23:
wherein the pharmacological chaperone is administered in an amount effective to increase trafficking of the mutant MC4R polypeptide to the cell membrane.
13. The method of claim 12 , wherein the pharmacological chaperone is administered in a pharmaceutically-acceptable carrier.
14. The method of claim 12 , wherein the pharmacological chaperone is administered orally.
15. The method of claim 12 , wherein the mutant MC4R polypeptide comprises the mutation P78L, R165Q, R165W, C271Y, T11A, A175T, I316L, 1316S, 1317T, N97D, G98R, N62S, C271R, S58C, N97D, Y157S, I102S, L106P, L250Q or Y287X.
16. The method of claim 15 , wherein the mutant MC4R polypeptide comprises the mutation S58C, N62S, R165Q, R165W, or C271Y.